Savient visits FDA re Krystexxa manufacturing changes; Schering Plough plans long goodbye for 160 plant workers;

> Savient Pharmaceuticals is on the FDA's calendar today following last year's rejection of gout treatment Krystexxa due to concerns over manufacturing changes. Story

> Schering Plough will eliminate 160 jobs on a voluntary basis over three years at its west Cork manufacturing plant. Article 

> Rio de Janeiro drugmaker Mantecorp has adopted Mitsubishi automation controllers and the open-technology CC-Link industrial communication network in a renovation of two facilities totaling 350,000 square meters. News

> DHL has teamed with frozen transport and packaging systems provider CryoPort to offer drugmakers speedy access to the latter's CryoPort Express Shipper and preferred DHL shipping rates. CryoPort release

> Advaxis has begun a manufacturing program for clinical quantities of human-grade ADXS31-164, a live Listeria vaccine that targets Her2 tumors. Advaxis release

Suggested Articles

Popular logic says you never switch horses, or CDMOs, in the middle of the stream, but Acacia Pharma had to do that to win an FDA approval.

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.